Bevacizumab biosimilar, recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A). Indications: colorectal cancer, ovarian and cervical cancer, lung cancer, renal cell cancer, glioblastoma, breast cancer. Currently > 48 000 patients treated, > 1 900 000 vials sold, marketed in 27 countries.

*Numbers of vials/patients treated relevant as of January 2022. The calculation of patients is based on the average recommended doses, average patient weight, and the approximate duration of therapy